Physician profile
Michael S Lux
NPI 1295701688
$2,292.66
in general payments reported to CMS, 2019-2025
30 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $190 · 2021: $181 · 2022: $355 · 2023: $362 · 2024: $315 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $396.49 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $275.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $162.17 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $128.12 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $123.80 | 2019-2022 | |
| Baxter Healthcare | $116.26 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $115.10 | 2020-2025 | Cardiomems |
| Boston Scientific Corporation | $110.14 | 2019-2023 | Watchman Access System |
| Amarin Pharma, INC. | $93.68 | 2019-2021 | |
| Novo Nordisk INC | $82.98 | 2022-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.59 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.09 | 2019-2025 | Lifevest |
| Heartflow, INC. | $60.91 | 2023-2024 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $60.48 | 2023-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $46.90 | 2021-2025 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44.41 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $34.78 | 2024 | |
| Azurity Pharmaceuticals, INC. | $31.56 | 2023-2025 | Edarbi, Edarbi |
| Abiomed | $28.42 | 2019 | |
| Lundbeck LLC | $27.70 | 2020-2021 | |
| Irhythm Technologies, INC. | $27.62 | 2019 | |
| Akcea Therapeutics, INC. | $27.51 | 2020-2021 | |
| Philips North America LLC | $25.20 | 2025 | Extended Holter |
| Agepha Pharma Fz LLC | $25.03 | 2024 | Lodoco |
| Atricure, INC. | $23.65 | 2025 | Atriclip Laa Exclusion System |
| Bayer Healthcare Pharmaceuticals INC. | $21.90 | 2025 | |
| Cvrx, INC. | $18.45 | 2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $15.74 | 2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $14.83 | 2022 | |
| Esperion Therapeutics, INC. | $14.25 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.